Hoth Therapeutics (NASDAQ:HOTH) Receives “Buy” Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a research report sent to investors on Monday, Benzinga reports. HC Wainwright currently has a $4.00 price target on the stock.

A number of other research firms have also weighed in on HOTH. EF Hutton Acquisition Co. I upgraded Hoth Therapeutics to a “strong-buy” rating in a report on Wednesday, August 21st. Benchmark restated a “speculative buy” rating and set a $3.00 price objective on shares of Hoth Therapeutics in a research note on Friday, October 11th.

Hoth Therapeutics Stock Performance

HOTH opened at $0.89 on Monday. Hoth Therapeutics has a 1-year low of $0.58 and a 1-year high of $1.73. The company’s fifty day moving average price is $0.89 and its two-hundred day moving average price is $0.94.

Hoth Therapeutics (NASDAQ:HOTH) last posted its earnings results on Friday, August 9th. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.15. Equities analysts forecast that Hoth Therapeutics will post -1.18 earnings per share for the current year.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.